[图书][B] Targeting the Toxin B glucosyltransferase domain of NAP1/B1/027 Clostridioides difficile using an attenuated Salmonella enterica Typhimurium vaccine vector

P Upadhyaya - 2022 - search.proquest.com
Clostridioides difficile (C. difficile) is the most common cause of nosocomial antibiotic-
associated diarrhea in developed countries and is classified as an urgent threat by the …

[图书][B] Preclinical development of a novel vaccine targeting Clostridioides difficile using an attenuated Salmonella Typhimurium vector

K Winter - 2022 - search.proquest.com
Clostridioides difficile infection (CDI) is one of the most important nosocomial infections in
the world. In 2012, approximately 40,000 CDI cases were reported in Canada with a cost of …

Novel Chimeric Protein Vaccines Against Clostridium difficile Infection

S Wang, Y Wang, Y Cai, CP Kelly, X Sun - Frontiers in immunology, 2018 - frontiersin.org
Clostridium difficile infection (CDI) is the leading cause of world-wide nosocomial acquired
diarrhea in adults. Active vaccination is generally accepted as a logical and cost-effective …

[HTML][HTML] Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models

JH Tian, G Glenn, D Flyer, B Zhou, Y Liu, E Sullivan… - Vaccine, 2017 - Elsevier
Clostridium difficile is the number one cause of nosocomial antibiotic-associated diarrhea in
developed countries. Historically, pathogenesis was attributed two homologous …

Vaccination against Clostridium difficile by Use of an Attenuated Salmonella enterica Serovar Typhimurium Vector (YS1646) Protects Mice from Lethal Challenge

K Winter, L Xing, A Kassardjian, BJ Ward - Infection and immunity, 2019 - Am Soc Microbiol
Clostridium difficile disease is mediated primarily by toxins A and B (TcdA and TcdB,
respectively). The receptor binding domains (RBD) of TcdA and TcdB are immunogenic, and …

An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo

SM Baliban, A Michael, B Shammassian… - Infection and …, 2014 - Am Soc Microbiol
Clostridium difficile-associated disease (CDAD) constitutes a large majority of nosocomial
diarrhea cases in industrialized nations and is mediated by the effects of two secreted toxins …

Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) …

K Winter, S Houle, CM Dozois, BJ Ward - Microbiology Spectrum, 2024 - Am Soc Microbiol
Developing a vaccine against Clostridioides difficile is a key strategy to protect the elderly.
Two candidate vaccines using a traditional approach of intramuscular (IM) delivery of …

Development of an Effective Nontoxigenic Clostridioides difficile–Based Oral Vaccine against C. difficile Infection

S Wang, D Zhu, X Sun - Microbiology spectrum, 2022 - Am Soc Microbiol
The symptoms of Clostridioides difficile infection (CDI) are largely attributed to two C. difficile
toxins, TcdA and TcdB. Significant efforts have been devoted to developing vaccines …

Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains

S Secore, S Wang, J Doughtry, J Xie, M Miezeiewski… - PLoS …, 2017 - journals.plos.org
Clostridium difficile infections (CDI) are a leading cause of nosocomial diarrhea in the
developed world. The main virulence factors of the bacterium are the large clostridial toxins …

683. Understanding Clostridioides difficile toxinB gene conservation through surveillance of public data

K Mulholland, V Godfrey, AM Stanley… - Open Forum …, 2023 - academic.oup.com
Background Clostridioides difficile infection (CDI) is the leading cause of antibiotic and
healthcare-associated infective diarrhea. It is linked to 365,000 infections and causes …